Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl



Institución Fdn Arturo Lopez Perez

Publicaciones

Citas Totales

Instituciones en Colaboración

×

¿Quieres unificar este perfil a otros que correspondan al mismo autor? Recuerda, la unificación de perfiles permite fusionar las publicaciones, asociadas a distintas firmas, en una única firma llamada "base".
Esta operación no elimina las firmas de autor originales de una publicación. Tampoco altera otras bases de datos que no sean DataCiencia.

  • Paso 1: Pincha el botón de "Unificar Perfiles"
    • - Verás un listado de firmas en las cuales coincide el primer apellido y la primera letra del nombre. Costado izquierdo de la pantalla ("Sugerencias").
    • - Ese listado está acompañado de información sobre algunas publicaciones y afiliaciones.
  • Paso 2: Selecciona una firma como "Base". Escoge aquella firma más completa.
    • - Esta firma agrupará las publicaciones de las otras firmas.
    • - Por defecto, la primera firma del listado es la que contiene más publicaciones.
  • Paso 3: Selecciona una o varias firmas como "Agrupar".
    • - Las publicaciones y afiliaciones de estas firmas se añadirán a la firma base.
  • Paso 4: Ingresa tu correo electrónico.
    • - Este es un método de validación obligatorio.
    • - Solo una solicitud por correo electrónico.
  • Paso 5: Pincha el botón "Enviar solicitud".
    • - Recibirás un correo por tu solicitud la cual estará pendiente de evaluación.
    • - Recibirás un segundo correo cuando tu solicitud sea procesada de forma completa, parcial, o rechazada.


Continuar

* ¿Por qué es necesario unificar perfiles? Muchas veces las publicaciones vienen desde el origen (WoS, Scopus o SciELO) vinculadas a distintas firmas de autor a pesar de corresponder a las mismas personas.


Disciplinas de Investigación





Muestra la distribución de su producción desde 2008 por disciplinas.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

WOS #Pub
Oncology 120
Medicine, General & Internal 37
Radiology, Nuclear Medicine & Medical Imaging 33
Hematology 17
Surgery 14
Urology & Nephrology 13
Obstetrics & Gynecology 12
Respiratory System 9
Medicine, Research & Experimental 7
Health Care Sciences & Services 6
Multidisciplinary Sciences 5
Infectious Diseases 4
Dermatology 4
Immunology 4
Gastroenterology & Hepatology 4
Pharmacology & Pharmacy 3
Social Sciences, Biomedical 3
Cell Biology 3
Endocrinology & Metabolism 3
Public, Environmental & Occupational Health 3
Reproductive Biology 3
Psychology, Multidisciplinary 3
Biology 3
Psychology 3
Health Policy & Services 3
Otorhinolaryngology 2
Pathology 2
Biochemistry & Molecular Biology 2
Fisheries 2
Developmental Biology 2
Rehabilitation 1
Evolutionary Biology 1
Anesthesiology 1
Chemistry, Medicinal 1
Engineering, Biomedical 1
Psychology, Mathematical 1
Cell & Tissue Engineering 1
Geriatrics & Gerontology 1
Psychology, Experimental 1
Clinical Neurology 1
Genetics & Heredity 1
Mathematical & Computational Biology 1
Neurosciences 1
Dentistry, Oral Surgery & Medicine 1
Ecology 1
Biotechnology & Applied Microbiology 1
Zoology 1
Marine & Freshwater Biology 1
Materials Science, Biomaterials 1
Veterinary Sciences 1
Scopus #Pub
Oncology 59
Cancer Research 46
Radiology, Nuclear Medicine And Imaging 27
Medicine (All) 26
Hematology 12
Public Health, Environmental And Occupational Health 4
Infectious Diseases 4
Urology 3
Obstetrics And Gynecology 3
Developmental Biology 3
Pharmacology (Medical) 3
Biochemistry, Genetics And Molecular Biology (All) 2
Reproductive Medicine 2
Radiation 2
Endocrinology, Diabetes And Metabolism 2
Genetics 2
Surgery 2
Pharmacology 1
Biophysics 1
Biochemistry 1
Mechanics Of Materials 1
Ceramics And Composites 1
Biomaterials 1
Physiology (Medical) 1
Pulmonary And Respiratory Medicine 1
Bioengineering 1
Agricultural And Biological Sciences (All) 1
Immunology 1
Endocrinology 1
SciELO #Pub
Health Sciences 28
Biological Sciences 1

Bases de Datos



Muestra la distribución de las publicaciones de la institución en las distintas bases de datos* (WoS, Scopus y SciELO-Chile).

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

* Una misma publicación puede pertenecer a más de una base de datos.

Base de Datos #Publicaciones
WOS 275
Scopus 155
SciELO 23

Autores



Nombre Género #Pub

Muestra un listado ordenado de los autores afiliados a la institución en publicaciones desde 2008.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.



Muestra la distribución de los autores de la institución por género.
Para determinar el género de cada nombre de autor, afiliado a una institución nacional, se realiza un trabajo automático de detección a partir de un diccionario de nombres en constante actualización, además del trabajo interno realizado en los datos de forma permanente.

Es importante mencionar que si no se encuentra el nombre del autor en el diccionario (que está en permanente actualización) este no se contabiliza y su género es Indeterminado.

Porcentaje Indeterminados: 22.8 % del total de autores de esta institutición.

Muestra la productividad, basada en cantidad de publicaciones, de los autores afiliados a la institución.

Colaboración Institucional



Muestra la distribución de la colaboración de las instituciones Chilenas por tipo, en publicaciones desde 2008 en adelante.
Los tipos de colaboración se definen de la siguiente forma:

  • Sin colaboración: publicaciones en las cuales sólo participa la institución.
  • Internacional: además de la institución, hay autores de instituciones extranjeras.
  • Nacional: además de la institución, hay autores de otras instituciones chilenas.
  • Mixta: además de la institución, hay autores de otras instituciones chilenas y además extranjeras.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Muestra el número de publicaciones por tipo de colaboración en cada año desde 2008.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Distribución del Impacto WoS



Publicaciones Citas
Total Porcentaje Total Porcentaje Representativas Cuartil (Mediana)
Q1 112 53.1 % 9704 92.4 % 12
Q2 41 19.4 % 488 4.6 % 12
Q3 31 14.7 % 235 2.2 % 6
Q4 27 12.8 % 80 0.8 % 2.5
Q1 Distribución disciplinas OECD / WoS
Q2 Distribución disciplinas OECD / WoS
Q3 Distribución disciplinas OECD / WoS
Q4 Distribución disciplinas OECD / WoS

Origen de Citas Identificadas



Muestra la distribución de países cuyos autores citan las publicaciones del Institución consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 0.96 %
Citas No-identificadas: 99.04 %

Muestra la distribución de instituciones nacionales o extranjeras cuyos autores citan las publicaciones del Institución consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 0.96 %
Citas No-identificadas: 99.04 %

Liderazgo



El liderazgo se define porque los autores pertenecientes a la Institución son primer autor o autor de correspondencia en las publicaciones con afiliación a esta institución.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Publicaciones



Título Año Citas
Quantitative Circulating Tumor Dna (Ct Dna) Assessment In Patients (Pts) With Advanced Urothelial Carcinoma (Uc) Treated With Pembrolizumab (Pembro) Or Platinum Based Chemotherapy (Chemo) From The Phase 3 Keynote 361 Trial 2024 0
Decision Aids For People Facing Health Treatment Or Screening Decisions 2024 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): 4 Year (Yr) Follow Up Of Check Mate 649. 2024 0
Overall Survival With Adjuvant Pembrolizumab In Renal Cell Carcinoma 2024 0
First Line Nivolumab Plus Chemotherapy For Advanced Gastric, Gastroesophageal Junction, And Esophageal Adenocarcinoma: 3 Year Follow Up Of The Phase Iii Check Mate 649 Trial 2024 0
Pembrolizumab For Advanced Urothelial Carcinoma: Exploratory Ct Dna Biomarker Analyses Of The Keynote 361 Phase 3 Trial 2024 0
Pembrolizumab In Her2 Positive Gastric Cancer 2024 0
Cost Effectiveness Of Intraoperative Radiation Therapy Versus Intensity Modulated Radiation Therapy For The Treatment Of Early Breast Cancer: A Disinvestment Analysis 2024 0
Unraveling Germline Predisposition In Hematological Neoplasms: Navigating Complexity In The Genomic Era 2024 0
Development Of Geriatric Oncology In Latin America: A Report From The Latin American Cooperative Oncology Group 2024 0
Early Detection And Diagnostic Approach Through Automated Hematological Analysis For Plasma Cell Leukemia 2024 0
Multilocus Inherited Neoplasia Allele Syndrome: Report Of Uncommon Combinations Between Chek2/Atm And Brca1/Cdkn2 A Genes 2024 0
The Phenotypic Spectrum Of Spinocerebellar Ataxia Type 19 In A Series Of Latin American Patients 2024 0
Epidemiological And Clinical Characteristics Of Adult Acute Lymphoblastic Leukemia Patients In Chile: A Single Center Analysis 2024 0
Imaging Gr Pr Expression In Metastatic Castration Resistant Prostate Cancer With [68 Ga]Ga Rm2—A Head To Head Pilot Comparison With [68 Ga]Ga Psma 11 2024 0
Nivolumab Plus Docetaxel In Patients With Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer: Results From The Phase Ii Checkmate 9 Kd Trial 2023 0
Pazopanib In Locally Advanced Or Metastatic Renal Cell Carcinoma: Results Of A Randomized Phase Iii Trial 2023 1
Cpn Coverage Analysis: An R Package For Parameter Estimation In Conceptual Properties Norming Studies 2023 1
Prognostic Parameters On Baseline And Interim [<Sup>18</Sup>F]Fdg Pet/Computed Tomography In Diffuse Large B Cell Lymphoma Patients 2023 0
Primary Plasma Cell Leukemia In Latin America: Demographic, Clinical, And Prognostic Characteristics. A Study Of Gelamm Group 2023 2
A Nationwide Pilot Study On Breast Cancer Screening In Peru 2023 0
Another Cause Of Pseudobasophilia: Flower Cells 2023 1
Clinical And Histopathological Features Of Follicular Thyroid Cancer In Chile 2023 0
A Plain Language Summary Of The Check Mate 649 Study: Nivolumab In Combination With Chemotherapy Compared To Chemotherapy Alone For Untreated Advanced Or Metastatic Cancer Of The Stomach Or Esophagus 2023 0
Performance Estimation Of Two In House Elisa Assays For Covid 19 Surveillance Through The Combined Detection Of Anti Sars Co V 2 Ig A, Ig M, And Ig G Immunoglobulin Isotypes 2023 0
Dabrafenib Plus Trametinib Versus Nivolumab For Advanced Melanoma 2023 0
Anthracyclines Versus No Anthracyclines In The Neoadjuvant Strategy For Her2+Breast Cancer: Real World Evidence 2023 0
Cytoreductive Radical Prostatectomy Versus No Local Treatment In Patients With Metastatic Prostate Cancer 2023 0
Another Cause Of Pseudobasophilia: Flower Cells ( May 2023 , 10.1007/S12308 023 00548 5) 2023 0
First Line Nivolumab Plus Ipilimumab Plus Chemotherapy In Metastatic Nsclc: Check Mate 9 La 3 Year Update 2023 0
Consensus Of The Chilean Society Of Infectious Diseases For The Management Of Episodes Of Febrile Neutropenia In Adults And Children With Cancer Consenso De La Sociedad Chilena De Infectología Para El Manejo De Episodios De Neutropenia Febril En Adultos Y Niños Con Cáncer 2023 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): 3 Year Follow Up From Check Mate 649 2023 0
Systemic And Intracranial Outcomes With First Line Nivolumab Plus Ipilimumab In Patients With Metastatic Nsclc And Baseline Brain Metastases From Check Mate 227 Part 1 2023 2
Secondary Acute Myeloid Leukemia From A Previous Chronic Myeloproliferative Neoplasm: A Study Of Grelam Chile Concerning Chilean Patients On Behalf Of Aml Pethema Registry 2023 0
Efficacy And Safety Of Pembrolizumab And Chemotherapy In Newly Diagnosed, Early Unfavorable Or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote C11 Study 2023 0
First Graduate Of The Master Of Nursing In Advanced Practice In Oncology In Chile Primeira Graduada Do Mestrado Em Enfermagem Em Prática Avançada Em Oncologia No Chile Primera Graduada Del Magister En Enfermería De Práctica Avanzada En Oncología En Chile 2023 1
Y Adjuvant Pembrolizumab (Pembro) For Renal Cell Carcinoma (Rcc) Across Ucla Integrated Staging System (Uiss) Risk Groups And Disease Stage: Subgroup Analyses From The Keynote 564 Study. 2023 3
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): 3 Year Follow Up From Check Mate 649. 2023 10
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): 3 Year Follow Up From Check Mate 649 2023 0
Primary Bladder Sarcoma: A Multi Institutional Experience From The Rare Cancer Network 2023 0
How Public Policies Have Improved The Overall Survival Of Transplant Eligible Newly Diagnosed Multiple Myeloma Patients In The Chilean Public Health System 2023 0
Dosimetric Comparison Of Thoracic Sbrt Planning In Monaco And Eclipse For The Elekta Agility Mlc 2023 0
Development Of A Safety Barrier Against Radiation Treatment Accidents Through A Python Script 2023 0
Timing Of Salvage Radiotherapy After Prostatectomy: From Randomized Trials To The Real World 2023 0
Recommendations About The Programming Of Medical Activities In Medical Oncology Of The Chilean Society Of Medical Oncology 2023 0
Local Advances And Challenges In The Molecular Diagnosis Of Solid Tumors: A Health Perspective Towards Precision Oncology In Chile 2023 0
Update On The Diagnosis And Stratification Of Patients With Acute Myeloid Leukemia: An Urgent National Need 2023 0
Findings Of A Breast Cancer Screening Program With Mammography In Chile 2023 0
Brain Relapse In Her2 Positive Breast Cancer After Neoadjuvant Treatment: An International Multicentric Study 2023 0
Phase 1/ 2 Study Of Quavonlimab (Qmab) Plus Pembrolizumab (Pembro) In Patients (Pts) With Advanced Melanoma That Progressed On A Pd 1/Pd L1 Inhibitor 2022 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Check Mate 649 Biomarker Analyses 2022 0
Association Between Gene Expression Signatures And Outcomes Of Pembrolizumab (Pembro) And Paclitaxel (Pac) In Advanced Gastric Cancer (Gc): Exploratory Analysis From Keynote 061 2022 0
Germline Pathogenic Variant Prevalence Among Latin American And Us Hispanic Individuals Undergoing Testing For Hereditary Breast And Ovarian Cancer: A Cross Sectional Study 2022 0
Health Related Quality Of Life (Hr Qo L) With Pembrolizumab (Pembro) Plus Chemotherapy (Chemo) Vs Placebo (Pbo) + Chemo As 1 L Treatment For Advanced Triple Negative Breast Cancer (Tnbc): Results From Keynote 355 2022 0
Nivolumab Plus Docetaxel In Patients With Chemotherapy Nai Spacing Diaeresis Ve Metastatic Castration Resistant Prostate Cancer: Results From The Phase Ii Check Mate 9 Kd Trial 2022 19
Sbrt Boost For Intermediate And High Risk Prostate Cancer. Results Of A Single Chilean Institution 2022 0
Sbrt Monotherapy For Low And Intermediate Risk Prostate Cancer. First Chilean Experience. 2022 0
Simple Model For A 3 D Assessment Of Peripheral Dose In Coplanar Isocentric Photon Radiotherapy 2022 0
Water Based Acrylic Marker For Reflectance Confocal Microscopy Lesion Delineation 2022 0
Highlights Of The 'I Congress Ecancer Choosing Wisely' March 30 And 31, 2022 Santa Cruz, Bolivia 2022 0
Methods To Collect Communities' Values And Preferences About Health Systems Coverage 2022 0
Complementary And Alternative Therapies In Skin Cancer A Literature Review Of Biologically Active Compounds 2022 0
First Line Therapy With Nivolumab (Nivo) Plus Ipilimumab (Ipi)+2 Cycles Of Chemotherapy (Chemo) Vs Chemotherapy Alone (4 Cycles) In Patients (Pts) With Metastatic Non Small Cell Lung Cancer (M Nsclc): 3 Year Update Of Check Mate 9 La 2022 0
Survival And Response Deepening After Autologous Transplantation In Patients With Multiple Myeloma In Chile 2022 0
First Line (1 L) Nivolumab (Nivo) Plus Ipilimumab (Ipi)+2 Cycles Of Chemotherapy (Chemo) Vs Chemo Alone (4 Cycles) In Patients (Pts) With Metastatic Non Small Cell Lung Cancer (M Nsclc): 3 Year Update From Check Mate 9 La 2022 0
First Line (1 L) Nivolumab (Nivo) Plus Ipilimumab (Ipi)+2 Cycles Of Chemotherapy (Chemo) Versus Chemo Alone (4 Cycles) In Patients (Pts) With Metastatic Non Small Cell Lung Cancer (Nsclc): 3 Year Update From Check Mate 9 La. 2022 7
Clinical Characteristics Of Chilean Adult Patients With Acute Myeloid Leukemia (Aml): Analysis Within The Framework Of The Epidemiological Registry Of Aml Of The Pethema Group 2022 0
Pegathor Lymphoma, A Phase 2 Study Of Sar444245 As A Monotherapy Or In Combination With Pembrolizumab For The Treatment Of Adults And Adolescents With Relapsed Or Refractory B Cell Lymphoma 2022 0
Evaluation Of The Health Technology Assessment Process Of The Financial Protection System For High Cost Diagnoses And Treatments In Chile (Ricarte Soto Law) 2022 1
A Simple Analytical Model For A Fast 3 D Assessment Of Peripheral Photon Dose During Coplanar Isocentric Photon Radiotherapy 2022 0
Tumor Cell Syk Expression Modulates The Tumor Immune Microenvironment Composition In Human Cancer Via Tnf α Dependent Signaling 2022 2
Mutational Landscape And Actionable Target Rates On Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience 2022 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Versus Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Expanded Efficacy, Safety, And Subgroup Analyses From Check Mate 649 2022 11
Nivolumab Plus Chemotherapy Or Ipilimumab In Gastro Oesophageal Cancer 2022 88
First Line Nivolumab Plus Ipilimumab In Advanced Nsclc: 4 Year Outcomes From The Randomized, Open Label, Phase 3 Check Mate 227 Part 1 Trial 2022 122
Update On Neuroendocrine Tumors 2021 0
Accounting For Relatedness And Spatial Structure To Improve Plant Phenotypic Selection In The Wild 2021 0
Diagnostic Accuracy Of <Sup>18</Sup>F Psma 1007 Pet/Ct Imaging For Lymph Node Staging Of Prostate Carcinoma In Primary And Biochemical Recurrence 2021 54
Hypofractionated Versus Conventional Intensity Modulated Postmastectomy Radiotherapy: Toxicity And Quality Of Life In Patients With Tissue Expander Breast Reconstruction 2021 0
First Line Nivolumab Plus Ipilimumab Combined With Two Cycles Of Chemotherapy In Patients With Non Small Cell Lung Cancer (Check Mate 9 La): An International, Randomised, Open Label, Phase 3 Trial 2021 549
Sin Ex Db 2.0 Update 2020: Database For Eukaryotic Single Exon Coding Sequences 2021 0
Modelling Cost Effectiveness Of Syphilis Detection Strategies In Prisoners: Exploratory Exercise In A Chilean Male Prison 2021 1
Can Kidney Parenchyma Metabolites Serve As Prognostic Biomarkers For Long Term Kidney Function After Nephrectomy For Renal Cell Carcinoma? A Preliminary Study 2021 1
Full Recombinant Flagellin B From <I>Vibrio Anguillarum</I> (R Fla) And Its Recombinant D1 Domain (R Nd1) Promote A Pro Inflammatory State And Improve Vaccination Against P. <I>Salmonis</I> In Atlantic Salmon (S. Salar) 2021 8
Early Versus Deferred Anti Sars Co V 2 Convalescent Plasma In Patients Admitted For Covid 19: A Randomized Phase Ii Clinical Trial 2021 51
Durvalumab In Locally Advanced Nsclc In Latam: Real World Data From Patients Included In The Early Access Program 2021 0
First Line Nivolumab Plus Ipilimumab Versus Chemotherapy In Advanced Nsclc With 1% Or Greater Tumor Pd L1 Expression: Patient Reported Outcomes From Check Mate 227 Part 1 2021 28
Lenvatinib Plus Pembrolizumab For Patients With Previously Treated Biliary Tract Cancers In The Multicohort Phase Ii Leap 005 Study. 2021 28
Check Mate 9 Kd Arm B Final Analysis: Efficacy And Safety Of Nivolumab Plus Docetaxel For Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer. 2021 8
Biomarker Discovery In Patients With Immunotherapy Treated Melanoma With Imaging Mass Cytometry 2021 27
Impact Of The Time Interval Between Primary Melanoma Excision And Sentinel Node Biopsy: A Systematic Review And Meta Analysis 2021 1
Consensus For Treatment Of Metastatic Castration Sensitive Prostate Cancer: Report From The First Global Prostate Cancer Consensus Conference For Developing Countries (Pcccdc) 2021 6
Consensus On The Treatment And Follow Up For The Nonmetastatic Castration Resistant Prostate Cancer: A Report From The First Prostate Cancer Consensus Conference For Developing Countries 2021 3
Overall Survival In Patients With Resected Glioblastoma Treated With Adjuvant Therapy: A Retrospective Study In A Public Hospital In Chile 2021 1
A New Smoothened Antagonist Bearing The Purine Scaffold Shows Antitumour Activity In Vitro And In Vivo 2021 8
Adjuvant Pembrolizumab After Nephrectomy In Renal Cell Carcinoma 2021 278
Lenvatinib Plus Pembrolizumab For Patients With Previously Treated Biliary Tract Cancers In The Multicohort Phase 2 Leap005 Study 2021 0
Lenvatinib Plus Pembrolizumab For Patients With Previously Treated Biliary Tract Cancers In The Multicohort Phase 2 Leap 005 Study. 2021 12
Early Salvage Radiotherapy In The Post Radicals Rt Era: The Gap From Trials To Reality 2021 0
First Line (1 L) Nivolumab (Nivo) Plus Chemotherapy (Chemo) Versus Chemo In Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Expanded Efficacy And Safety Data From Check Mate 649. 2021 11
Ver más publicaciones y descargar CSV

Listado ordenado de publicaciones desde 2008 y sus citas.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.


Descargar Descarga los datos de esta página (formato JSON).
Descargar Descarga los datos de esta página como un archivo Excel.